Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year

uent to the acquisition. Acquired in-process research and development, a charge related to the purchase accounting of the OBS acquisition, totaled $3.8 billion for 2007. Equity income in 2007 totaled $2.0 billion, an increase of 40 percent compared to 2006.

Recent Developments

The company also offered the following summary of recent significant developments that have previously been announced, including:

-- Reported on results from two Phase II studies in patients with vascular

disease showing that TRA, a novel oral thrombin receptor antagonist,

does not increase the rate of major or minor bleeding in patients with

acute coronary syndrome or prior ischemic stroke when added to standard

antiplatelet therapy. (Announced Oct. 22, 2007)

-- Reported long-term follow-up results with the European Organization for

the Research and Treatment of Cancer Phase III trial that showed the

combination of TEMODAR (temozolomide) Capsules and radiation therapy

significantly prolonged survival in patients with glioblastoma

multiforme. (Announced Oct. 30, 2007)

-- Reported that the U.S. District Court for the District of Massachusetts

found no liability for Warrick Pharmaceuticals, the company's generic

subsidiary, in a class action lawsuit regarding average wholesale

prices for prescription products. (Announced Nov. 5, 2007)

-- Gained European Commission approval of PEGINTRON (peginterferon alfa-

2b) and REBETOL (ribavirin) combination therapy for retreating adult

patients with chronic hepatitis C whose prior treatment did not result

in a sustained response. (Announced Nov. 15, 2007)

-- Completed the acquisition of Organon BioSciences N.V. (Announced Nov.

19, 2007)

-- Merck/Schering-Plough Pharmaceuticals announced that an independent

panel of clinical and biostatistics experts had b

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
(Date:10/7/2015)... Calif. , Oct. 7, 2015  ChromaDex ... wellness and nutritional ingredients that creates science-based solutions ... sports nutrition, and pharmaceutical products, today announced that ... , CEO and Founder, is now available for ...   -->   ...
(Date:10/7/2015)... , Oct. 7, 2015  October is National Liver ... has committed to donating a portion of its October ... and hepatology practices. ... in a variety of ways; whether it is by ... world, collaborating with researchers in different disease and investigation ...
(Date:10/7/2015)... ... October 07, 2015 , ... Park Systems , ... Coatings to provide a comprehensive overview of the innovations in smart coatings using ... . This webinar will be given by Professor Roberto Advincula, professor with ...
(Date:10/7/2015)... ... October 07, 2015 , ... Tunnell Consulting , Inc. ... the Operational and Process Improvement practice. He brings to his role more than ... “I am delighted that Dr. Matzmorr is joining our team,” said Dr. Philippe Cini, ...
Breaking Biology Technology:
... Following the,establishment of their Industrial Management Board, ... is happy to announce its,official launch event to ... of M.B.N Nanomaterialia, the board members Mr Manfred ... Andrea Reinhardt of microTEC,look forward to a very ...
... Fame Coach Jim Calhoun Credits Early Diagnosis with ... two of AdvaMed 2007:,The MedTech Conference will highlight how ... technology as well as speakers on the,diversity and strength ... conference runs Oct. 1 through Oct. 3., Co-writing ...
... October 2 - Management and Distinguished ... Development Programs, as Well as on,the microRNA Field ... a global leader in,microRNA-based diagnostics and therapeutics, announced ... and their significant potential in cancer,treatment and other ...
Cached Biology Technology:
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
Breaking Biology News(10 mins):
... tissues into mice, researchers report in the November Cell ... normal and obese mice. The findings suggest that the hormone ... insulin resistance and type 2 diabetes. , Insulin resistance, in ... sugar (glucose) levels, is a precursor to diabetes. ...
... Cancer Symposium features the latest findings in laboratory, translational ... on new and promising therapeutic approaches, as well as ... To help you take the best advantage of ... you to visit to view the ...
... N.Y. (Mon., Nov. 3, 2008) Understanding the ... tissues requires experimental systems that allow for the study ... laboratory. This month,s issue of Cold Spring ... with detailed instructions for setting up these experimental culture ...
Cached Biology News:
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Biology Products: